ArticleMicrosystems & nanoengineering2026
High-fidelity bioassembly of organoids and spheroids using inertial droplet microfluidics for precision oncology and tumor microenvironment modeling.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The translation of 3D multicellular systems into clinical applications has been constrained by the need to balance physiological relevance and scalability. Current biofabrication methods primarily depend on passive cell aggregation or capillary- and viscosity-limited segmentation, resulting in stochastic heterogeneity that limits high-throughput screening (HTS). Here, we present OsciSphere, a chip-free droplet microfluidic platform that utilizes Weber-number-driven inertial forces to enable deterministic bioassembly of uniform 3D multicellular systems. Through programmable oscillatory acceleration, OsciSphere achieves precise, high-frequency droplet generation in standard well plates, eliminating the requirement for complex microfabrication. We demonstrate the versatility of this platform by generating miniaturized multicellular tumor spheroids (µMCTs) for drug screening, tissue-derived organoids (µTDOs) for pharmacological studies, and patient-derived organoids (µPDOs) that support tumor-immune co-cultures. In comparison to conventional Matrigel domes, OsciSphere-assembled 3D multicellular systems display improved uniformity, viability, and chemosensitivity. The platform's scalability enabled the screening of 49 commensal gut bacterial secretomes, leading to the identification of Eubacterium species that modulate cancer apoptotic pathways. Furthermore, µPDOs generated with OsciSphere support efficient infiltration of autologous PBMCs, enabling quantitative assessment of PD-1 blockade. This platform provides a robust, accessible approach to bridging the gap between complex tissue modeling and large-scale functional screening in precision oncology.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.